Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 165-172 , May 2010

Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS)

  • Charlton Wilson, MD

      Affiliations

    • Phoenix Indian Medical Center, 4212 N 16th Street, Phoenix, AZ, 85016, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Chun-Chih Huang, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA
    • ,
  • Nawar Shara, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA
    • ,
  • Barbara V. Howard, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA
    • ,
  • Jerome L. Fleg, MD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    • ,
  • Jeffrey A. Henderson, MD, MPH

      Affiliations

    • Black Hills Center for American Indian Health, Rapid City, SD, USA
    • ,
  • Wm. James Howard, MD

      Affiliations

    • Washington Hospital Center, Washington, DC, USA
    • ,
  • Heather Huentelman, PharmD

      Affiliations

    • Phoenix Indian Medical Center, 4212 N 16th Street, Phoenix, AZ, 85016, USA
    • ,
  • Elisa T. Lee, PhD

      Affiliations

    • University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    • ,
  • Mihriye Mete, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA
    • ,
  • Marie Russell, MD

      Affiliations

    • Phoenix Indian Medical Center, 4212 N 16th Street, Phoenix, AZ, 85016, USA
    • ,
  • James M. Galloway, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    • ,
  • Angela Silverman, MSN, CANP

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA
    • ,
  • Mario Stylianou, PhD

      Affiliations

    • National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    • ,
  • Jason Umans, MD, PhD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA
    • ,
  • Matthew R. Weir, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, MD, USA
    • ,
  • Fawn Yeh, PhD

      Affiliations

    • Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    • ,
  • Robert E. Ratner, MD

      Affiliations

    • MedStar Research Institute, Hyattsville, MD, USA

Received 27 January 2010 ,Accepted 29 January 2010.

References 

  1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care. 1979;2:120–126
  2. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389–401
  3. Butler WJ, Ostrander LD, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh Study: long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol. 1985;121:541–547
  4. Howard BV. Macrovascular complications of diabetes mellitus. In:  LeRoith D,  Taylor SI,  Olefs JM editor. Diabetes Mellitus. Philadelphia: Lippincott-Raven; 1996;p. 792–797
  5. Klein R. Kelly West Lecture 1994: hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258–268
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  7. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), NIH Publication No. 98-4080 (1997) [No. 98–4080].
  8. Pyòrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620
  9. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713–2721
  10. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  11. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485
  12. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275–279
  13. Dahlof B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  14. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–B64
  15. Patel A, MacMahon S, Chalmers J, Neal B, et al. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–840
  16. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in American Indians: The Strong Heart Study. Circulation. 1999;99:2389–2395
  17. Howard B, Roman MJ, Fleg JL, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The Stop Atherosclerosis In Native Diabetics Study (SANDS). JAMA. 2008;299:1678–1689
  18. In:  Gold MR,  Siegel JE,  Russell LB,  Weinstein MC editor. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996;
  19. Herman WH. Economic analyses of diabetes interventions: rationale, principles, findings and interpretation. Endocrinologist. 1999;9:113–117
  20. Russell M, Fleg JL, Galloway WJ, et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J. 2006;152:867–875
  21. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  22. Center for Medicare & Medicaid Services. 2009 Jan 7. Physician Fee Schedule Search Physician Fee Schedule Look-up. Available at: http://www.cms.hhs.gov/PFSlookup/02_PFSSearch.asp. Accessed May 29, 2009.
  23. Red Book Wholesale Drug Prices. In: Red Book Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Healthcare; 2008;
  24. Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP. The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care. 1998;10:509–520
  25. Pyne JM, Sieber WJ, David K, Kaplan RM, Rapaport MH, Williams DK. Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients. J Affect Disord. 2003;76:237–247
  26. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;23:203–235
  27. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy studies.". Med Decis Making. 2000;20:451–467
  28. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–2551
  29. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369–390
  30. Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of air bags by seating position. JAMA. 1997;278:1418–1425
  31. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393

PII: S1933-2874(10)00047-4

doi: 10.1016/j.jacl.2010.01.008

Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 165-172 , May 2010

Article Tools